UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 404

Sortiert nach

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

Critical reviews in oncology/hematology, 2016-04, Vol.100, p.88-98

2016

Volltextzugriff (PDF)

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

The New England journal of medicine, 2020-09, Vol.383 (12), p.1139-1148

2020

Volltextzugriff (PDF)

Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities

Critical reviews in oncology/hematology, 2014-01, Vol.89 (1), p.140-165

2014

Volltextzugriff (PDF)

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

The New England journal of medicine, 2014-11, Vol.371 (20), p.1867-1876

2014

Volltextzugriff (PDF)

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

The lancet oncology, 2016-09, Vol.17 (9), p.1248-1260

2016

Volltextzugriff (PDF)

Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient

European journal of cancer (1990), 2018-05, Vol.95, p.130-132

2018

Volltextzugriff (PDF)

Statins to prevent anthracycline-related myocardial toxicity: The jury is still out

European journal of internal medicine, 2024-08, Vol.126, p.41-42

2024

Volltextzugriff (PDF)

Wnt/β-catenin signaling in melanoma: preclinical rationale and novel therapeutic insights

Cancer treatment reviews, 2016-09, Vol.49, p.1-12

2016

Volltextzugriff (PDF)

Rational combination of cancer immunotherapy in melanoma

Virchows Archiv : an international journal of pathology, 2019-04, Vol.474 (4), p.433-447

2019

Volltextzugriff (PDF)

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma

Journal of clinical oncology, 2018-12, Vol.36 (35), p.3441-3449

2018

Volltextzugriff (PDF)

Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications

Cancer treatment reviews, 2020-08, Vol.88, p.102060-102060, Article 102060

2020

Volltextzugriff (PDF)

Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients

Expert opinion on drug safety, 2020-10, Vol.19 (10), p.1229-1236

2020

Volltextzugriff (PDF)

Delayed cold-type autoimmune hemolytic anemia responding to Rituximab in a melanoma patient treated with Ipilimumab and Nivolumab

European journal of cancer (1990), 2023-11, Vol.193, p.113320-113320, Article 113320

2023

Volltextzugriff (PDF)

Colorectal cancer and cardiovascular diseases: Are we closing the gap between knowledge and action?

European journal of internal medicine, 2021-05, Vol.87, p.13-14

2021

Volltextzugriff (PDF)

Nras in melanoma: Targeting the undruggable target

Critical reviews in oncology/hematology, 2014-11, Vol.92 (2), p.107-122

2014

Volltextzugriff (PDF)

Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism

European journal of cancer (1990), 2021-05, Vol.148, p.371-381

2021

Volltextzugriff (PDF)

Tissue prognostic biomarkers in primary cutaneous melanoma

Virchows Archiv : an international journal of pathology, 2014-03, Vol.464 (3), p.265-281

2014

Volltextzugriff (PDF)

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma

Journal of clinical oncology, 2022-12, Vol.40 (36), p.4178-4188

2022

Volltextzugriff (PDF)

Targeting BRAF in melanoma: Biological and clinical challenges

Critical reviews in oncology/hematology, 2013-09, Vol.87 (3), p.239-255

2013

Volltextzugriff (PDF)

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

Journal of clinical oncology, 2022-05, Vol.40 (13), p.1428-1438

2022

Volltextzugriff (PDF)

Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis

Cancer treatment reviews, 2021-11, Vol.100, p.102280-102280, Article 102280

2021

Volltextzugriff (PDF)

Treatment of venous thromboembolism in cancer patients: The dark side of the moon

Cancer treatment reviews, 2021-05, Vol.96, p.102190-102190, Article 102190

2021

Volltextzugriff (PDF)

Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review

International journal of molecular sciences, 2021-12, Vol.23 (1), p.147

2021

Volltextzugriff (PDF)

1 – 25 von 404

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(361)
Mit Volltextzugriff
(376)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient

Statins to prevent anthracycline-related myocardial toxicity: The jury is still out

Wnt/β-catenin signaling in melanoma: preclinical rationale and novel therapeutic insights

Rational combination of cancer immunotherapy in melanoma

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma

Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications

Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Delayed cold-type autoimmune hemolytic anemia responding to Rituximab in a melanoma patient treated with Ipilimumab and Nivolumab

Colorectal cancer and cardiovascular diseases: Are we closing the gap between knowledge and action?

Nras in melanoma: Targeting the undruggable target

Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism

Tissue prognostic biomarkers in primary cutaneous melanoma

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma

Targeting BRAF in melanoma: Biological and clinical challenges

Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis

Treatment of venous thromboembolism in cancer patients: The dark side of the moon

Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review

Suchergebnisse filtern